[go: up one dir, main page]

WO2000053744A3 - Selection finale d'une evolution dirigee - Google Patents

Selection finale d'une evolution dirigee Download PDF

Info

Publication number
WO2000053744A3
WO2000053744A3 PCT/US2000/006497 US0006497W WO0053744A3 WO 2000053744 A3 WO2000053744 A3 WO 2000053744A3 US 0006497 W US0006497 W US 0006497W WO 0053744 A3 WO0053744 A3 WO 0053744A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
molecules
obtaining
stochastic
provides methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/006497
Other languages
English (en)
Other versions
WO2000053744A2 (fr
WO2000053744A9 (fr
Inventor
Jay M Short
Gerhard Johann Frey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF Enzymes LLC
Original Assignee
Diversa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/267,118 external-priority patent/US6238884B1/en
Priority claimed from US09/276,860 external-priority patent/US6352842B1/en
Priority claimed from US09/332,835 external-priority patent/US6537776B1/en
Priority to IL14516500A priority Critical patent/IL145165A0/xx
Application filed by Diversa Corp filed Critical Diversa Corp
Priority to JP2000603365A priority patent/JP2002537836A/ja
Priority to AU38793/00A priority patent/AU3879300A/en
Priority to EP00917887A priority patent/EP1161529A2/fr
Priority to CA002361927A priority patent/CA2361927A1/fr
Publication of WO2000053744A2 publication Critical patent/WO2000053744A2/fr
Publication of WO2000053744A3 publication Critical patent/WO2000053744A3/fr
Publication of WO2000053744A9 publication Critical patent/WO2000053744A9/fr
Anticipated expiration legal-status Critical
Priority to US10/151,469 priority patent/US20030219752A1/en
Priority to AU2005203719A priority patent/AU2005203719A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C12N15/1027—Mutagenizing nucleic acids by DNA shuffling, e.g. RSR, STEP, RPR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Ecology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Cette invention concerne des techniques permettant d'obtenir des polynucléotides et des polynucléotides codés en utilisant des techniques non stochastiques d'évolution dirigées (DirectEvolution™). La possibilité de récupérer des polynucléotides de pleine longueur issus d'une bibliothèque de molécules d'une lignée générées par mutagenèse présente un avantage particulier dans les techniques fondées sur une sélection finale. Ces techniques comprennent des mutagenèses à saturation de site non stochastiques de polynucléotides (Gene Site Saturation Mutagenesis™) et un réassemblage de polynucléotides non stochastique (GeneReassembly™). Cette invention concerne des techniques permettant d'obtenir des enzymes aux propriétés physiques et/ou biologiques optimisées. Par l'utilisation de ces techniques de l'invention, on peut faire évoluer des vaccins génétiques, des enzymes, de petites molécules et d'autres molécules qui conviennent vers les propriétés souhaitées. On peut, par exemple, obtenir des vecteurs de vaccin qui font preuve d'une meilleure efficacité lorsqu'on les utilise comme vaccins génétiques. Les vecteurs ainsi obtenus peuvent avoir, par exemple, une expression antigénique renforcée, une absorption dans la cellule améliorée, une meilleure stabilité dans la cellule, une capacité à concevoir une réponse immune et d'autres propriétés de ce genre. Cette invention concerne en outre des techniques permettant d'obtenir diverses molécules biologiques actives, dans le domaine des antibiotiques, des pharmacothérapeutiques, et des caractères transgéniques.
PCT/US2000/006497 1995-12-07 2000-03-09 Selection finale d'une evolution dirigee Ceased WO2000053744A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA002361927A CA2361927A1 (fr) 1999-03-09 2000-03-09 Selection finale d'une evolution dirigee
EP00917887A EP1161529A2 (fr) 1999-03-09 2000-03-09 Selection finale d'une evolution dirigee
AU38793/00A AU3879300A (en) 1999-03-09 2000-03-09 End selection in directed evolution
IL14516500A IL145165A0 (en) 1999-03-09 2000-03-09 End selection in directed evolution
JP2000603365A JP2002537836A (ja) 1999-03-09 2000-03-09 定方向進化におけるエンドセレクション
US10/151,469 US20030219752A1 (en) 1995-12-07 2002-05-17 Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
AU2005203719A AU2005203719A1 (en) 1999-03-09 2005-08-18 End selection in directed evolution

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US09/267,118 1999-03-09
US09/267,118 US6238884B1 (en) 1995-12-07 1999-03-09 End selection in directed evolution
US09/276,860 US6352842B1 (en) 1995-12-07 1999-03-26 Exonucease-mediated gene assembly in directed evolution
US09/276,860 1999-03-26
US09/332,835 1999-06-14
US09/332,835 US6537776B1 (en) 1999-06-14 1999-06-14 Synthetic ligation reassembly in directed evolution

Related Child Applications (2)

Application Number Title Priority Date Filing Date
PCT/US1997/012239 Continuation-In-Part WO1998001581A1 (fr) 1996-07-09 1997-07-09 Methode de remaniement d'adn avec des polynucleotides obtenus par blocage ou interruption d'un processus de synthese ou d'amplification
US10/151,469 Continuation-In-Part US20030219752A1 (en) 1995-12-07 2002-05-17 Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof

Publications (3)

Publication Number Publication Date
WO2000053744A2 WO2000053744A2 (fr) 2000-09-14
WO2000053744A3 true WO2000053744A3 (fr) 2001-01-18
WO2000053744A9 WO2000053744A9 (fr) 2001-06-28

Family

ID=27401940

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/006497 Ceased WO2000053744A2 (fr) 1995-12-07 2000-03-09 Selection finale d'une evolution dirigee

Country Status (6)

Country Link
EP (1) EP1161529A2 (fr)
JP (1) JP2002537836A (fr)
AU (1) AU3879300A (fr)
CA (1) CA2361927A1 (fr)
IL (1) IL145165A0 (fr)
WO (1) WO2000053744A2 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537776B1 (en) * 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
US6326204B1 (en) 1997-01-17 2001-12-04 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
US7148054B2 (en) 1997-01-17 2006-12-12 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
US7390619B1 (en) 1998-02-11 2008-06-24 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
US7153655B2 (en) 1998-06-16 2006-12-26 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence
AU6510799A (en) 1998-10-07 2000-04-26 Maxygen, Inc. Dna shuffling to produce nucleic acids for mycotoxin detoxification
US6368861B1 (en) 1999-01-19 2002-04-09 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US6917882B2 (en) 1999-01-19 2005-07-12 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US6961664B2 (en) 1999-01-19 2005-11-01 Maxygen Methods of populating data structures for use in evolutionary simulations
US7024312B1 (en) 1999-01-19 2006-04-04 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
EP1108781A3 (fr) 1999-01-19 2001-09-12 Maxygen, Inc. Procédé de formation de chaínes de caractères, polynucléotides et polypéptides
IL138206A (en) * 1999-02-04 2011-06-30 Verenium Corp Methods for non-stochastic generation of progeny polypeptides and hybrid polynucleotides
US6531316B1 (en) 1999-03-05 2003-03-11 Maxyag, Inc. Encryption of traits using split gene sequences and engineered genetic elements
US7430477B2 (en) 1999-10-12 2008-09-30 Maxygen, Inc. Methods of populating data structures for use in evolutionary simulations
US6686515B1 (en) 1999-11-23 2004-02-03 Maxygen, Inc. Homologous recombination in plants
US7115712B1 (en) 1999-12-02 2006-10-03 Maxygen, Inc. Cytokine polypeptides
SG121902A1 (en) 2000-01-11 2006-05-26 Maxygen Inc Integrated systems for diversity generation and screening
WO2002000897A2 (fr) 2000-06-23 2002-01-03 Maxygen, Inc. Nouveaux promoteurs chimeres
EP1360290A2 (fr) 2000-06-23 2003-11-12 Maxygen, Inc. Molecules costimulatrices
US6858422B2 (en) 2000-07-13 2005-02-22 Codexis, Inc. Lipase genes
JP2002199890A (ja) * 2000-10-23 2002-07-16 Inst Of Physical & Chemical Res 生分解性ポリエステル合成酵素の改変方法
US6958213B2 (en) 2000-12-12 2005-10-25 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
US6958217B2 (en) 2001-01-24 2005-10-25 Genomic Expression Aps Single-stranded polynucleotide tags
EP1423529B1 (fr) * 2001-01-24 2013-11-20 Genomic Expression APS Dosage d'analyse d'expression genique
US8008459B2 (en) 2001-01-25 2011-08-30 Evolva Sa Concatemers of differentially expressed multiple genes
WO2002059297A2 (fr) 2001-01-25 2002-08-01 Evolva Biotech A/S Échantillothèque pour collection de cellules
WO2002092780A2 (fr) * 2001-05-17 2002-11-21 Diversa Corporation Nouvelles molecules de liaison a un antigene destinees a des applications therapeutiques, diagnostiques, prophylactiques, enzymatiques, industrielles et agricoles et procedes de generation et de criblage de telles molecules
EP1504098B2 (fr) 2002-05-17 2011-02-09 Alligator Bioscience AB Methode de developpement moleculaire in vitro d'une fonction de proteine
US20040219579A1 (en) * 2003-02-19 2004-11-04 Natasha Aziz Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
EP2502990B1 (fr) * 2006-10-30 2015-07-22 Promega Corporation Protéines d'hydrolase mutante avec expressions cinétique et fonctionnelle améliorées
US9476032B2 (en) 2007-03-30 2016-10-25 The Research Foundation For The State University Of New York Attenuated viruses useful for vaccines
EP2980217A1 (fr) * 2007-12-31 2016-02-03 XOMA Technology Ltd. Procédés et matériaux pour mutagenèse ciblée
CN110498822A (zh) * 2019-09-04 2019-11-26 上海药明康德新药开发有限公司 DNA编码化合物库构建中on-DNA芳基叠氮化合物的合成方法

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0285123A2 (fr) * 1987-04-03 1988-10-05 Stabra AG Méthode de mutagénèse complète d'acides nucléiques
US5223408A (en) * 1991-07-11 1993-06-29 Genentech, Inc. Method for making variant secreted proteins with altered properties
WO1995022625A1 (fr) * 1994-02-17 1995-08-24 Affymax Technologies N.V. Mutagenese d'adn par fragmentation aleatoire et reassemblage
US5512463A (en) * 1991-04-26 1996-04-30 Eli Lilly And Company Enzymatic inverse polymerase chain reaction library mutagenesis
WO1997020078A1 (fr) * 1995-11-30 1997-06-05 Maxygen, Inc. Procede d'elaboration de polynucleotides presentant des caracteristiques desirees par selection iterative et recombinaison
WO1998001581A1 (fr) * 1996-07-09 1998-01-15 Recombinant Biocatalysis, Inc. Methode de remaniement d'adn avec des polynucleotides obtenus par blocage ou interruption d'un processus de synthese ou d'amplification
WO1998013487A1 (fr) * 1996-09-27 1998-04-02 Maxygen, Inc. Procedes permettant l'optimisation d'une therapie genique grace a un rearrangement et une selection recursifs de sequences
WO1998027230A1 (fr) * 1996-12-18 1998-06-25 Maxygen, Inc. Procedes et compositions pour l'ingenierie des polypeptides
WO1998032845A1 (fr) * 1997-01-24 1998-07-30 Bioinvent International Ab Procede d'evolution moleculaire in vitro de la fonction proteique
US5798208A (en) * 1990-04-05 1998-08-25 Roberto Crea Walk-through mutagenesis
WO1998042832A1 (fr) * 1997-03-25 1998-10-01 California Institute Of Technology Recombinaison de sequences de polynucleotides au moyen d'amorces aleatoires ou definies
US5824469A (en) * 1986-07-17 1998-10-20 University Of Washington Method for producing novel DNA sequences with biological activity
WO1998058080A1 (fr) * 1997-06-16 1998-12-23 Bioinvent International Ab Procede permettant l'evolution moleculaire in vitro d'une fonction proteique

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824469A (en) * 1986-07-17 1998-10-20 University Of Washington Method for producing novel DNA sequences with biological activity
EP0285123A2 (fr) * 1987-04-03 1988-10-05 Stabra AG Méthode de mutagénèse complète d'acides nucléiques
US5798208A (en) * 1990-04-05 1998-08-25 Roberto Crea Walk-through mutagenesis
US5512463A (en) * 1991-04-26 1996-04-30 Eli Lilly And Company Enzymatic inverse polymerase chain reaction library mutagenesis
US5223408A (en) * 1991-07-11 1993-06-29 Genentech, Inc. Method for making variant secreted proteins with altered properties
WO1995022625A1 (fr) * 1994-02-17 1995-08-24 Affymax Technologies N.V. Mutagenese d'adn par fragmentation aleatoire et reassemblage
WO1997020078A1 (fr) * 1995-11-30 1997-06-05 Maxygen, Inc. Procede d'elaboration de polynucleotides presentant des caracteristiques desirees par selection iterative et recombinaison
WO1998001581A1 (fr) * 1996-07-09 1998-01-15 Recombinant Biocatalysis, Inc. Methode de remaniement d'adn avec des polynucleotides obtenus par blocage ou interruption d'un processus de synthese ou d'amplification
WO1998013487A1 (fr) * 1996-09-27 1998-04-02 Maxygen, Inc. Procedes permettant l'optimisation d'une therapie genique grace a un rearrangement et une selection recursifs de sequences
WO1998027230A1 (fr) * 1996-12-18 1998-06-25 Maxygen, Inc. Procedes et compositions pour l'ingenierie des polypeptides
WO1998032845A1 (fr) * 1997-01-24 1998-07-30 Bioinvent International Ab Procede d'evolution moleculaire in vitro de la fonction proteique
WO1998042832A1 (fr) * 1997-03-25 1998-10-01 California Institute Of Technology Recombinaison de sequences de polynucleotides au moyen d'amorces aleatoires ou definies
WO1998058080A1 (fr) * 1997-06-16 1998-12-23 Bioinvent International Ab Procede permettant l'evolution moleculaire in vitro d'une fonction proteique

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GE L ET AL: "SIMULTANEOUS INTRODUCTION OF MULTIPLE MUTATIONS USING OVERLAP EXTENSION PCR", BIOTECHNIQUES,US,EATON PUBLISHING, NATICK, vol. 22, no. 1, 1997, pages 28,30, XP000676361, ISSN: 0736-6205 *
RIECHMANN L AND WEILL M: "Phage display and selection of a site-directed randomized single-chain antibody Fv fragment for its affinity improvement", BIOCHEMISTRY, vol. 32, no. 34, 31 August 1993 (1993-08-31), pages 8848 - 8855, XP002147197 *
SCHULTZ S ET AL: "Site-saturation studies of beta-lactamase: production and characterization of mutant beta-lactamases with all possible amino acid substitutions at residue 71", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 83, no. 6, March 1986 (1986-03-01), pages 1588 - 1592, XP002147196 *
ZHAO H ET AL: "MOLECULAR EVOLUTION BY STAGGERED EXTENSION PROCESS (STEP) IN VITRO RECOMBINATION", NATURE BIOTECHNOLOGY,US,NATURE PUBLISHING, vol. 16, 1 March 1998 (1998-03-01), pages 258 - 261, XP000775867, ISSN: 1087-0156 *

Also Published As

Publication number Publication date
CA2361927A1 (fr) 2000-09-14
JP2002537836A (ja) 2002-11-12
EP1161529A2 (fr) 2001-12-12
AU3879300A (en) 2000-09-28
IL145165A0 (en) 2002-06-30
WO2000053744A2 (fr) 2000-09-14
WO2000053744A9 (fr) 2001-06-28

Similar Documents

Publication Publication Date Title
WO2000053744A3 (fr) Selection finale d'une evolution dirigee
WO2000046344A3 (fr) Elaboration non stochastique de vaccins genetiques et d'enzymes
EP2397549A3 (fr) Génération non stochastique de vaccins génétiques et enzymes
WO2002057664A3 (fr) Nouvelles proteines insecticides du bacillus thuringiensis
WO2001047952A3 (fr) Proteines insecticides provenant de bacillus thuringiensis
WO2001019859A3 (fr) COMPOSITIONS D'ENDOTOXINES δ DU BACILLUS THURINGIENSIS ACTIVES CONTRE LES LEPIDOPTERES, ET LEURS PROCEDES D'UTILISATION
WO2002016655A3 (fr) Sequences nucleotidiques de plantes a stress regule, plantes transgeniques contenant ces sequences, et methodes d'utilisation stress-regulated nucleotide sequences of plants, transgenic plants containing same, and methods of use
DE69131321D1 (de) Mutationen in der 5'-3'-exonukleaseaktivität thermostabiler dna-polymerasen
IL193087A0 (en) Dan from a reconbinant poxvirus expressing homologous genes inserted into the poxviral genome
EP2284259A3 (fr) Protéases
WO2005030926A3 (fr) Variants de glycoside hydrolases
EP1988099A3 (fr) Protéines insecticides de Bacillus thuringiensis
JP6799329B2 (ja) バクテリオファージ、青枯病防除剤及び青枯病防除方法
EP1373480A4 (fr) Mecanismes d'action productifs et cataboliques non couples des cellules hotes
WO2002016549A3 (fr) Procedes de traitement ou de prevention de maladies auto-immunes au moyen d'un polynucleotide renfermant du cpg
WO1999057282A3 (fr) Toxines pesticides et sequences nucleotidiques codant pour ces toxines
EP1001025A3 (fr) Protéines principales de la membrane externe de actinobacillus pleuropneumoniae
WO2005058945A3 (fr) Variants genetiques codant pour des proteines issues de la voie metabolique de produits chimiques fins
WO2001072974A3 (fr) Sequence genique
CN104694558B (zh) 一种酯酶基因estZ及其编码的蛋白质和应用
SG128684A1 (en) Novel sequence and utilization thereof
CN111961656B (zh) 一种丝氨酸羟甲基转移酶的突变体及其用途
CN104178504A (zh) 氨基甲酸酯类农药降解酶CFH与其编码基因cfd以及二者的应用
Tong et al. Complete nucleotide sequence of a Chinese duck hepatitis B virus
WO2006029343A3 (fr) Peptides ciblant selectivement le systeme cardio-vasculaire et conjugues et procedes associes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/11-11/11, DRAWINGS, REPLACED BY NEW PAGES 1/7-7/7; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWE Wipo information: entry into national phase

Ref document number: 145165

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PA/A/2001/009091

Country of ref document: MX

Ref document number: 38793/00

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2000 603365

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2000917887

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2361927

Country of ref document: CA

Ref document number: 2361927

Country of ref document: CA

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2000917887

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000917887

Country of ref document: EP